Nimetazepam

Structural formula
General
Non-proprietary name	Nimetazepam
other names	1-methyl-7-nitro-5-phenyl-3 H -1,4-benzodiazepin-2-one ( IUPAC )
Molecular formula	C 16 H 13 N 3 O 3
External identifiers / databases
EC number	217-931-5
ECHA InfoCard	100.016.302
PubChem	4496
ChemSpider	4340
Wikidata	Q6149812
Drug information
ATC code	N05
Drug class	Benzodiazepine; Hypnotic;
properties
Molar mass	295.3 g · mol -1
Melting point	156.5-157.5 ° C
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
H and P phrases	H: 225-301-311-331-370
	P: 210-260-264-280
Toxicological data	910 mg kg −1 ( LD 50 , mouse , oral ) ; 1150 mg kg −1 ( LD 50 , rat , oral ) ;
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Nimetazepam is a hypnotic from the group of benzodiazepines . It is the N-methylated derivative of Nitrazepam and was developed by Hoffmann-La Roche in 1962 . It has amnestic , anxiolytic , anticonvulsant , hypnotic , sedative and muscle relaxing potential. It is used for the short-term treatment of severe sleep disorders. Nimetazepam was launched in 1978 by Sumitomo Dainippon Pharma under the trade name Erimin . The substance is not available in Germany.

Nimetazepam is one of the medium-acting benzodiazepines with an elimination half-life of 14 to 30 hours. The bioavailability when taken orally is almost 100% and it is characterized by the fastest onset of action of all oral benzodiazepines. The equivalent dose to 10 mg diazepam is 10 mg nimetazepam. Like all hypnotics from the benzodiazepine class, nimetazepam has a high potential for dependence and abuse. However, due to the particularly rapid onset of action, the abuse potential with this particular benzodiazepine is particularly high.

Trade names

Monopreparations

Erimin (JP, withdrawn from the market in 2015), Lavol (TW), Sunime (TW)

Individual evidence

↑ ^a ^b ^c George W. A. Milne (Ed.): Drugs . Definitions and properties. Routledge, 2018, ISBN 978-1-351-78989-9 ( limited preview in Google Book Search).
↑ ^a ^b Safety Data Sheet. (PDF) In: caymanchem.com. Cayman Chemical, accessed March 26, 2019 .
↑ Patent US3109843 : Process for preparing 5-phenyl-1,2-dihydro-3H-1,4-benzodiazepines. Published on November 5, 1963 , Applicant: Hoffmann-La Rouche Inc, Inventor: Reeder E., Sternbach LH. ‌
↑ Global Brand Database - brand data from multiple national and international sources: Erimin® WIPO Global Brand Database. In: WIPO Global Brand Database. WIPO, October 24, 1978, accessed March 26, 2019 .
↑ Stolerman (Ed.): Encyclopedia of Psychopharmacology . Nimetazepam. Springer Science & Business Media, 2010, ISBN 978-3-540-68698-9 ( limited preview in Google book search).
↑ Toshiya Inada, Ataru Inagaki: Psychotropic dose equivalence in Japan. . In: Psychiatry and Clinical Neurosciences . 69, No. 8, 2015, p. 445. doi : 10.1111 / pcn.12275 . PMID 25601291 .

[GoogleBuch-1] George W. A. Milne (Ed.): Drugs . Definitions and properties. Routledge, 2018, ISBN 978-1-351-78989-9 ( limited preview in Google Book Search).

[MSDS-2] Safety Data Sheet. (PDF) In: caymanchem.com. Cayman Chemical, accessed March 26, 2019 .

[3] Patent US3109843 : Process for preparing 5-phenyl-1,2-dihydro-3H-1,4-benzodiazepines. Published on November 5, 1963 , Applicant: Hoffmann-La Rouche Inc, Inventor: Reeder E., Sternbach LH. ‌

[4] Global Brand Database - brand data from multiple national and international sources: Erimin® WIPO Global Brand Database. In: WIPO Global Brand Database. WIPO, October 24, 1978, accessed March 26, 2019 .

[HWZ-5] Stolerman (Ed.): Encyclopedia of Psychopharmacology . Nimetazepam. Springer Science & Business Media, 2010, ISBN 978-3-540-68698-9 ( limited preview in Google book search).

[6] Toshiya Inada, Ataru Inagaki: Psychotropic dose equivalence in Japan. . In: Psychiatry and Clinical Neurosciences . 69, No. 8, 2015, p. 445. doi : 10.1111 / pcn.12275 . PMID 25601291 .